'With continuous disclosure laws, if it was not possible for the Her-Vaxx OS trial to complete then we would have been notified as such, similar to how the Mesoblast Covid-19 ARDS trial was stopped when it was determined that it would not reach the 30 day improvement end point values.'
If someone can explain to me how the trial can be concluded that'd be great. The only outrageous (but possible) explanation I can think of is that IMU cannot rule out the possibility, however unlikely, that the IDMC might allow the trial to restart. IMU's defence could be that they cannot know the mind of the IDMC. Beyond that preposterous excuse I can't see why the trial hasn't been declared ended. One thing is for sure - they're not waiting on any more patients so all talk about longer is better is bs.
Not investment advice.
Ann: FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX, page-90
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.8¢ |
Change
0.001(1.75%) |
Mkt cap ! $424.5M | |||
| Open | High | Low | Value | Volume |
| 5.8¢ | 6.2¢ | 5.8¢ | $1.143M | 19.26M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 2125808 | 5.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.9¢ | 103000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
5.8¢ |
Change
0.001 ( 1.75 %) |
||||
| Open | High | Low | Volume | ||
| 5.8¢ | 6.2¢ | 5.8¢ | 6209843 | ||
| Last updated 15.59pm 13/06/2024 ? | |||||
| IMU (ASX) Chart |